Fig. 8: In vivo tumor hypoxia imaging performance and anti-tumor efficacy in MCF-7 tumor bearing mice model.

a Schematic representation of the anti-tumor efficacy study process. The green circle emblemizes intravenous drug administration (n = 6 mice per group). b In vivo fluorescence imaging of MCF-7 tumor-bearing mice following intravenous administration of PBS, SMNB, and SHC4H. c Ex vivo images of tumors and major organs captured 24 h after injection and d a corresponding analysis of MFI (n = 3 independent experiments; mean values  ±  SD). p value represents SHC4H group versus SMNB group at 24 h. e Tumor growth curves in each group during treatment (n = 6 mice per group; mean values  ±  SD). f Tumor weights of different groups at the experimental endpoint (n = 5 mice per group; mean values  ±  SD). g Images of the tumors obtained from each experimental group (n = 5 mice per group). h Body weight changes in different groups during the experimental period (n = 6 mice per group; mean values  ±  SD). i Expression of LC3 and p62 of MCF-7 tumor in BALB/c-nu mice via Western Blot analysis (left) and the quantification of the ratio of LC3-II to LC3I and p62 to β-actin expression (right), n = 4 independent experiments, mean values  ±  SD. j Immunofluorescence staining for evaluating the expression levels of mitophagy-related proteins (Parkin) and anti-apoptotic protein (Bcl-2) in tumor tissues from each experimental group. Blue fluorescence represents DAPI-stained nuclei (n = 4 independent experiments; mean values  ±  SD). Scale bar = 100 μm. k Immunofluorescence TUNEL staining for assessing the apoptosis of tumors (n = 4 independent experiments; mean values  ±  SD). Scale bar = 100 μm. l p-Ripk3 and p-Mlkl immunohistochemical staining in the tumor tissues after different treatments (n = 4 independent experiments; mean values  ±  SD). Scale bar = 100 μm. Statistical differences were assessed using one-way ANOVA followed by a Tukey post-hoc test. Source data are provided as a Source Data file.